Welcome to Helix Talk, an educational podcast for healthcare students and providers covering real-life clinical pearls, professional pharmacy topics, and drug therapy discussions.

This podcast is provided by pharmacists and faculty members at Rosal Franklin University College of Pharmacy.

This podcast contains general information for educational purposes only. This is not

professional advice and should not be used in lieu of obtaining advice from a qualified

health care provider. And now on to the show. Welcome to Helix Talk episode 125. I'm your co-host

Dr. Kane. And I'm Dr. Patel. And in this episode, I'm so excited

to talk about Warfarin. And not just any aspect of Warfarin, but kind of like the pharmacogenomics

aspect where we consider polymorphism and what kind of impact those have in our clinical

recommendation.

And so the title of our topic today is, let's get personal talking boyfriend pharmacogenomics.

So Dr. Patel, you know, we talked about DNA with our conversation with Rosalyn Franklin's niece

and how it was so cool that her work way back in the

early 1950s has basically led the way to what we now have as commercialization of pharmacogenomics

and understanding how your genome can impact how drugs work in your body.

And warfarin is one of those drugs in the sense that now we have a lot of

information about how your genetics can play a role in whether you metabolize Warfarin more or

less or are more sensitive to Warfarin or not, things like that. Yeah, I mean, working with

warfarin in an outpatient clinic, you know, I do have first an experience of like how just managing Warprint as is with

so many variable factors that could impact the outcome of therapy, it's complicated. It's not,

you know, an easy answer. But then you add this polymorphism and pharmacogenomic implications,

you know, on top of it. And it just becomes even more confusing.

And so kind of the disclaimer out here, I do the regular warfarin management, you know,

...